'Real Life' Monitoring of COPD no ICS Patients

Inclusion Criteria: * COPD diagnosis according to GOLD 2017 recommendations in clinical stability phase * Post bronchodilator FEV1 ≥50 and ≤80 * Both smoker and ex-smoker * Patients on LABA or LABA/LAMA therapy * Patients also on ICS therapy discontinued at least 30 days after enrolment * Patient able to cooperate with the required procedures * Patient who has signed the informed consent Exclusion Criteria: * \- Acute respiratory episode treated with antibiotics and/or steroids in the lower 4 weeks prior to enrolment * Patients on roflumilast therapy * Any exacerbation of COPD within 1 month after visit 1. A patient must not have had any hospitalisation for COPD within 6 months prior to visit 1. * Comorbidities. History or current evidence of a clinically significant comorbidity or history of a positive test for HIV, hepatitis B or hepatitis C. * History of adverse reactions including immediate or delayed hypersensitivity to any beta2-agonists, * sympathomimetic drugs or any intranasal, inhaled or systemic corticosteroid therapy known or suspected sensitivity to the components of the inhalers used in the study (e.g. lactose in dry powder inhalers). * Use of immunosuppressive drugs within 12 weeks prior to visit 1 and during the study, including use of systemic corticosteroids.